Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLargo, Inc. filings document an operating company with cleantech, environmental engineering and life sciences subsidiaries, including disclosures tied to product and service revenue, partially owned subsidiaries, debt obligations and common stock. Registration statements and related exhibits describe common stock, capital structure, resale registration rights and equity financing arrangements.
BioLargo's Form 8-K filings record Regulation FD materials, investor presentation exhibits, annual operating-result releases, shareholder town hall transcripts, material definitive agreements and officer compensation converted into common stock. The filings also provide formal disclosure around governance, liquidity, subsidiary activity and risk factors associated with commercializing water treatment, medical technology, engineering services and energy-storage businesses.
BioLargo, Inc. (BLGO) furnished an investor presentation under Item 7.01 (Regulation FD). The company plans to present the slide deck attached as Exhibit 99.1 during an investor webcast on November 14, 2025 at 1:30 PM Pacific Time.
The information is expressly stated as furnished, not filed, and is not subject to liability under Section 18 of the Exchange Act nor incorporated by reference into other filings. The company notes Safe Harbor language applies to forward-looking statements in the slides. Exhibits include 99.1 (slide deck) and 104 (Cover Page Inline XBRL).
BioLargo, Inc. (BLGO) furnished investor presentation materials under Item 7.01 (Regulation FD). The company plans to present the slides attached as Exhibit 99.1 at the LD Micro Main Event XIX at the Hotel del Coronado in San Diego on October 20 at 2:00 p.m. Pacific Time.
The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, is not incorporated by reference into other SEC filings, and may be updated through future public disclosures.
Jack B. Strommen, a director of BioLargo, Inc. (BLGO), received an option grant of 88,235 shares on 09/30/2025 under the company's 2024 Equity Incentive Plan. The option has an exercise price of $0.17 per share, is exercisable beginning 09/30/2025, and expires 09/30/2035. After this grant, Mr. Strommen directly beneficially owns 2,278,121 shares of common stock. The filing states the option was issued as payment for $15,000 of board fees for the most recently completed quarterly period. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and is reported as an individual filing by one reporting person.
Linda Park, a director of Biolargo, Inc. (BLGO), received 110,294 stock options on 09/30/2025 at a $0.17 exercise price that vest/exercise beginning 09/30/2025 and expire 09/30/2035. The filing shows she now directly beneficially owns 1,164,025 shares of common stock after the reported transaction. The options were issued as payment for $18,750 of board fees under the Issuer's 2024 Equity Incentive Plan. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 10/02/2025.
Christina Elaine Bray, a director of Biolargo, Inc. (BLGO), received an option to purchase 110,294 shares of common stock at an exercise price of $0.17 per share on 09/30/2025. The option is exercisable on 09/30/2025 and expires on 09/30/2035. The filing reports that the option was issued as payment for $18,750 in director fees under the issuer's 2024 Equity Incentive Plan. After this grant, Ms. Bray beneficially owns 1,164,025 shares of Biolargo common stock, held directly. The Form 4 was executed on 10/02/2025 and filed under Section 16 reporting requirements.
Marshall Dennis E, a director of Biolargo, Inc. (BLGO), reported option grants on 09/30/2025. Two options to purchase common stock were acquired: 132,351 shares exercisable at $0.17 per share (expiring 09/30/2035) and 110,294 shares exercisable at $0.17 per share (expiring 09/30/2035). The first option replaces a previously issued option for 34,615 shares that expired unexercised; the replacement was made under the issuer’s Compensation Committee plan in lieu of $22,500 in services. The second option was issued as payment of $18,750 in board fees under the 2024 Equity Incentive Plan. Following the reported grants, beneficial ownership figures shown are 4,957,267 and 5,067,561 shares on the respective lines. The Form 4 was signed by attorney-in-fact John R. Browning on 10/02/2025.
BioLargo, Inc. disclosed that its long‑standing license and manufacturing relationship with Pooph Inc. has broken down, and it has issued notice revoking Pooph’s license and terminating the License Agreement with 150 days’ notice after Pooph failed to pay agreed royalties and product invoices. Pooph has stated it will stop ordering from BioLargo, pursue its own formula for Pooph‑branded products, and terminate the Preferred Master Manufacturing Agreement, which BioLargo disputes, citing its contractual right to withhold product when payment terms were not met.
BioLargo also reported that a $3,486,000 note receivable tied to Pooph royalties and product invoices on its June 30, 2025 balance sheet may need to be written down, and management expects any impairment of this asset to be substantial, signaling a potentially significant financial hit related to this customer relationship.